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ABSTRACT 
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic 
syndrome and become one of the most common causes of chronic liver disease over the last 
decade in developed countries. The general prevalence of NAFLD is reported ranging 
between 20–30 % and 87 % in obese people. It is commonly associated with visceral obesity, 
type 2 diabetes mellitus, dyslipidemia and hypertension, all components of the metabolic 
syndrome, so that NAFLD might be considered an additional component of metabolic 
syndrome itself. As the rate of obesity, diabetes, and metabolic syndrome continue to 
increase, NAFLD will bring a tremendous impact on health care in the upcoming years. The 
underlying causes of the disease progression in NAFLD are unclear. Recent evidences suggest 
the development of lipid droplets (steatosis), subsequent generation of reactive oxygen 
species (ROS) and fibrosis deposition in the progression to non-alcoholic steatohepatitis 
(NASH). Moreover, continued elucidation has needed to understand fibrosis progression and 
regression. The paradigm of hepatic stellate cell (HSCs) activation remains the foundation for 
defining key translational challenges in order to accelerate the development of new therapies 
for patients with chronic liver disease.  
L-Carnitine (LCARN) is an essential nutrient that converts fat into energy in 
mitochondria. LCARN plays an important role in lipid metabolism; it acts as an essential 
cofactor for the β-oxidation of fatty acids. Very recently, LCARN has been proposed for the 
treatment of various diseases, including liver injury and several studies have shown that 
LCARN administration can ameliorate or prevent liver damage of various etiologies. 
We investigated the potential antioxidant and antifibrotic role of LCARN 
supplementation on methionine choline deficient (MCD)-diet-induced NAFLD in C57BL/6 
mice. Mice were divided into three groups of CONTR (normal diet without any treatment), 
MCDD (MCD diet only), MCDD+LCARN 200 mg/kg/die group. Liver and heart weight, 
histological changes and fibrosis progression were assessed after 6 weeks of experiments. The 
MCD-diet induced severe hepatic fatty accumulation, but the fatty change was reduced in the 
MCDD+LCARN group. LCARN supplementation showed a role in controlling liver ROS 
generation and consequently coordinating the HSCs activation. Additionally, the same 
antioxidant and antifibrotic effect was observed in the myocardium. In conclusion, our 
findings indicate that LCARN has a potential role in control NAFLD progression to NASH. 
Therefore, our data suggest that LCARN may acts as a novel and potent supplementation 
agent against NAFLD cardiac complications. 
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RIASSUNTO  
La steatosi epatica non alcolica (NAFLD), manifestazione epatica della sindrome 
metabolica, è diventata una delle più comuni cause di malattia epatica cronica negli ultimi 
dieci anni nei paesi sviluppati. La prevalenza generale della NAFLD è compresa tra il 20-30% 
e 87% nelle persone obese. È stata comunemente associata all’obesità viscerale, il diabete di 
tipo 2, la dislipidemia e l’ipertensione, tutti componenti della sindrome metabolica, portando 
la NAFLD ad essere di conseguenza considerata un’ulteriore componente della sindrome 
metabolica stessa. Poiché il tasso di obesità, diabete e sindrome metabolica è in continuo 
aumento, è stato previsto che la NAFLD nei prossimi anni avrà un enorme impatto sulla 
sanità. Ad oggi, le cause alla base della progressione della malattia non sono ancora state 
chiarite del tutto. Recenti evidenze hanno suggerito lo sviluppo di depositi lipidici (steatosi), 
la successiva generazione di specie reattive dell'ossigeno (ROS) e deposizione fibrotica come 
causa dello sviluppo della steatoepatite non alcolica (NASH). Nonostante questo, il continuo 
studio di questi meccanismi sarà fondamentale per comprendere l’attivazione della 
deposizione di collagene, il suo controllo e la regressione della malattia. Il paradigma 
d’attivazione delle cellule stellate epatiche (HSCs), rimane tuttora la chiave per la definizione 
e lo sviluppo di nuove terapie per i pazienti affetti da malattia epatica cronica. 
L-Carnitina (LCARN) è un nutriente essenziale in grado di trasformare il grasso in 
energia nei mitocondri. LCARN svolge un ruolo importante nel metabolismo dei lipidi; agisce 
come un cofattore essenziale per la β-ossidazione degli acidi grassi. Recentemente, LCARN è 
stata proposta per il trattamento di varie malattie compreso il danno epatico e numerosi studi 
hanno dimostrato che la somministrazione di LCARN può migliorare o prevenire danni al 
fegato di varie eziologie. 
Lo scopo della tesi è stato di studiare il potenziale antiossidante e antifibrotico di 
LCARN somministrata come integratore alimentare in un modello murino NAFLD indotto da 
dieta priva di metionina e colina (MCD). I topi C57BL/6 sono stati divisi in tre gruppi: 
CONTR (dieta normale senza alcun trattamento), MCDD (dieta MCD), MCDD+LCARN 200 
mg/kg/die (MCDD+LCARN). Il peso del fegato e del cuore, le alterazioni istologiche dei due 
organi e l’attivazione della fibrosi sono state valutate dopo 6 settimane. L’integrazione con 
LCARN ha ridotto l’accumulo di lipidi epatici, la generazione di ROS e l’attivazione della 
fibrosi sia epatica che cardiaca. In conclusione, i nostri risultati suggeriscono il potenziale 
ruolo di LCARN nel controllo non solo della progressione della NAFLD in NASH ma anche 
dello sviluppo delle complicazioni cardiache ad essa correlate. 
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1. INTRODUCTION 
1.1 Pathology of Non-Alcoholic Fatty Liver Disease 
The term nonalcoholic steatohepatitis (NASH), was firstly used in 1980 by Ludwig 
and colleague to describe the morphologic pattern of liver injury in 20 patients evaluated at 
the Mayo Clinic over a 10-year period (Ludwig J 1980). The 60% of these patients were 
female with no history of alcohol abuse, the 90% of these women were obese but incredibly, 
their liver biopsy had histological evidence of alcoholic hepatitis. In this population, diabetes 
mellitus and hyperlipidemia were also commonly described. Schaffner and colleague in the 
1986 with the term Non-Alcoholic Fatty Liver Disease (NAFLD), included a range of liver 
injuries and this designation became quickly the preferred one (Schaffner F 1986). The liver 
injuries included range from hepatic steatosis to NASH, characterized by fatty accumulation 
exceeding 5% of liver weight, hepatocellular injury, progressive fibrosis and has been defined 
both histologically and clinically (Brunt EM 2010). This distinction is important, as simple 
steatosis is unlikely to lead to liver related complications, whereas NASH may lead to 
increased fibrosis and cirrhosis, and its complications such as hepatocellular carcinoma 
(HCC) (Figure 1) (Sass DA 2005). The accepted scientific consensus is that NAFLD is not a 
benign condition and a subset of patients develop significant fibrosis or associated morbidity 
and mortality. Although, some of the pathological characteristic can be associated with 
hepatic fibrosis and the most important histological feature associated with mortality in 
NASH is presence of significant fibrosis. NAFLD is progressively being accepted as a 
clinically important disease, and as with any disease, the clinical importance is relative to its 
natural history and prevalence. The natural history of NAFLD is dynamic, with interaction 
and contribution from multiple factors including genetic, environmental and lifestyle factors. 
NAFLD proves to be a formidable disease entity, with considerable clinical burden, for both 
the present and the future (Goh GB 2016). 
In 1998 Day and James with the “Two Hits Hypothesis” described the development of 
NAFLD. This disease needs a two-step process dependent from each other. The first hit 
produce steatosis after a reversible hepatic lipid accumulation that prepare the liver for the 
second hit represented by a source of oxidative stress determining significant lipid 
peroxidation that facilitated inflammation, progressing steatosis and fibrosis (Day CP 1998). 
This hypothesis provides a rationale for the prevention and the control of disease progression 
in steatosis.  
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Figure 1. Progression of NAFLD (Adapted from Goh GB, 2016).  
 
1.1.1 First Hit - Lipid accumulation mechanism 
Liver plays a central role in the energy homeostasis by storing glucose as glycogen 
and distributing fuels in the form of glucose and lipids to peripheral organs. Hepatic glucose 
and free fatty acid uptake occurs and increase linearly with the postprandial rise in plasma 
concentrations. Dietary lipids in the form of chylomicrons are transported from the gut via the 
lymphatic system to the liver, where they are incorporated after release from lipoproteins by 
hepatic lipoprotein lipase (Bradbury MW 2004). Physiologically and during the postprandial 
phase, dietary lipids are stored in the liver, where they are processed and assembled with 
apolipoprotein B 100 o form very-low-density lipoprotein (VLDL). The molecular events 
resulting in intrahepatic lipid accumulation and growth of lipid droplets in hepatic steatosis 
are poorly understood, but may can be summarized in four different processes (Kallwitz ER 
2008): 
 Dietary calories in form of triglycerides are transported to the liver as 
chylomicrons. Moreover, adipose tissue triglycerides can reached the liver in 
form of free fatty acids (FFAs); 
 Increased De novo synthesis of triglycerides in the liver; 
 Decreased liver β-oxidation; 
 Decreased liver export of triglycerides as VLDL. 
In developed countries, the common cause of NAFLD is overnutrition that determined 
an excessive of extra-energy as lipid precursors from adipose tissue into ectopic depots such 
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as the liver (Valenti L 2016). The initial metabolic stress is represented by the hepatic lipid 
accumulation and overloading of mitochondrial capacity and is driven by lipotoxicity from 
FFAs (Figure 2). Lipotoxic effects of FFAs have been proposed to be the crucial factor in 
development and progression of hepatic steatosis. 
The modulation of hepatic triglyceride are coordinated by peroxisome proliferators 
activated receptors (PPARs), a nuclear receptor superfamily. There are three different PPARs 
isoforms in mammals: PPARα, PPARδ and PPARγ. PPARγ is the most intensively studied 
and it is also involved in the activation of genes that lead to improved uptake of glucose and 
lipids, increase glucose oxidation, and decrease FFAs concentration and insulin resistance. 
Recently, PPARγ is involved in an anti-inflammatory effect interfering with proinflammatory 
transcription factors as NFƙB, which is inhibited by physical interaction of PPARγ and p65 
and p50 NFƙB subunit (Anderson N 2008). 
 
 
 
Figure 2. Physiologic hepatic lipid metabolism and pathogenic mechanisms in metabolically induced 
NASH. The uptake, storage and excretion is balanced in physiological conditions but during the progression to 
NASH, the molecular events resulting in intrahepatic lipid accumulation and growth of lipid droplets are may 
arise from: 1) increased uptake of lipids increased, 2) elevated de novo synthesis of fatty acids, 3) impaired 
lipoprotein synthesis or secretion and/or 4) reduced fatty acid oxidation. (Adapted from Anderson N, 2008).  
 
As described in Figure 2, steatosis and its progression to steatohepatitis may also result 
from improper fatty acid oxidation (Anderson N 2008). Fatty acids oxidation is activated and 
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controlled by the AMP-activated protein kinase (AMPK). AMPK. is the downstream 
component of a protein kinase cascade that plays an important role in maintaining energy 
balance and plays an important role in whole-body energy metabolism (Kahn BB 2005) 
(Raney MA 1985). Activation of AMPK requires phosphorylation of threonine 172 (T172) 
within the T loop segment of the catalytic α subunit (D. M. Hawley SA 1996). The 
Ca
2+
/calmodulin-dependent protein kinase II (CaMKII), a serine-threonine kinase that is an 
important mediator of Ca
2+
, phosphorylates and activates AMPK kinase from rat liver (S. M. 
Hawley SA 1995). There are four CaMKII isoforms—α, β, γ, and δ—each encoded by a 
separate gene. The α and β isoforms are mostly neuronal, whereas CaMKIIγ and δ are 
expressed in a wide variety of tissues. After binding calcium/calmodulin complex, 
autophosphorylation on Thr287 results in calcium/calmodulin independent activity. CaMKII 
expression mediates the activation of AMPK primarily in response to Ca
2+
 (Woods A 2005).  
Ca
2+
 is the most abundant ion in the body, primarily stored in bones in the form of 
CaPO3. In bone, Ca
2+
 plays a structural role and also can be dissolved, serving as a source of 
cations in the blood (Pozzan T 1994). Ca
2+
 is a ubiquitous and versatile signaling molecule 
controlling a wide variety of cellular processes, including muscle contraction, neuronal 
transmission, hormone secretion, organelle communication, cellular motility, fertilization, and 
cell growth (Clapham DE 2007). Given these critical and diverse functions, cellular Ca
2+
 
concentration is tightly regulated, and dysfunction of cellular Ca
2+
 homeostasis is associated 
with several pathological conditions. Importantly, there is a bidirectional relationship between 
mitochondrial and cytosolic calcium. Changes in [Ca
2+
]c (Ca
2+ 
cytosolic) regulate 
mitochondrial oxidative metabolism, whilst the uptake of Ca
2+
 into mitochondria is important 
in buffering and shaping [Ca
2+
]c signals (Harzheim D 2009) (Gilabert JA 2000). Therefore 
mitochondrial function is essential not only to match energy supply with the stimulus-strength 
of glycogenolytic hormones, but also to regulate the amplitude, duration, propagation rates of 
[Ca
2+
]c and therefore finely tuned downstream biological responses. 
1.1.2 Second Hit - Oxidative stress mechanism  
Generation of oxidative stress (OS) is an important factor in lipotoxicity by virtue of 
its contribution to cellular stress signalling and interference with mitochondrial functions. 
Reactive oxygen species (ROS) are generated consequentially the hepatic lipid accumulation 
in NAFLD/NASH conditions. Overload of liver lipids induces the production of ROS and 
steatohepatitis and elevated production of ROS, contributes to organelle toxicity, suppression 
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of fatty acid oxidation, and an increase in lipid peroxidation (Figure 3) (Bartlett PJ 2014) 
(Rolo AP 2012). 
OS condition is the key features during different variety of pathophysiological 
conditions, by oxidizing membrane phospholipids, proteins, and nucleic acids. The duration 
of the oxidative injury modulates the cellular alterations and leads from plasma membrane 
changes (i.e. release of cytosolic substances and mitochondrial permeability) to necrosis 
condition (Ashraf NU 2015). Therefore, OS can be defined as an imbalance between 
productions of ROS and their elimination by protective mechanisms. 
Although periodic increases in mitochondrial matrix [Ca
2+
]m (Ca
2+ 
mitochondrial) are 
essential for normal cell function, sustained elevations in [Ca
2+
]m have deleterious effects on 
mitochondria and whole cell function and are associated with a number of disease states 
including metabolic syndrome and cardiac disease. Elevated [Ca
2+
]m results in enhanced flux 
through the electron transport chain which generates ROS (Rooney TA 1996). The effects of 
mitochondrially generated ROS are largely mitigated by the cellular antioxidant system via 
superoxide dismutase and glutathione. However, [Ca
2+
]m overload can lead to high levels of 
ROS formation leading to oxidative stress and ultimately cellular dysfunction (Hu F 2011). 
 
Figure 3. Schematic representation of oxidative stress role in disease progression (Adapted from Rolo 
AP, 2012). 
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Another important factor involved in this mechanism is the nuclear factor kappa B 
(NFκB). NFκB is a ubiquitous nuclear transcription factor in almost all cell types and is 
involved in numerous biological processes such as OS, inflammation, immunity, 
differentiation, cell growth, tumorigenesis and apoptosis. The NFκB has been described as a 
primary regulator and mediator of OS. It is widely accepted that OS plays crucial roles in the 
progression of liver injury and, consequently, in the activation of the fibrosis mechanism (Xu 
J 2003).  
It has been documented, that another important molecule that plays a critical roles in 
NASH, is the extracellular signal-regulated kinases-1/2 (ERK1/2), members of the mitogen-
activated protein kinase (MAPK) family with a crucial roles in cellular proliferation, survival, 
differentiation and homeostasis in normal conditions (Tormos AM 2013). The regulation of 
cell proliferation and differentiation mediated by growth factors and mitogens during 
development is mainly regulated by the ERK1/2 pathway (Turjanski AG 2007). In primary 
hepatocytes reduced survival during ROS exposure was observed when ERK activation was 
inhibited (Rosseland CM 2005) (Conde de la Rosa L 2006). Comparing primary hepatocytes 
from young rats (4–6 months) with primary hepatocytes from old rats (24–26 months), the old 
ones are more sensitive to H2O2-induced apoptosis. This decreased survival was associated 
with reduced activation of ERK, which protect against oxidant injury.  
Wang and colleague have been demonstrated that dysregulation of the hepatic ERK1/2 
signalling pathway was potential implicated in early-stage liver injury in NASH animal model 
fed a methionine and choline deficient diet (MCD diet), suggesting that might be represents a 
novel therapeutic choice for this disease (Wang Z. 2010) (Leclercq IA 2004). 
1.1.3 Inflammation  
In recent years, the role of the innate immune response in NAFLD has been the focus 
of intense research. During lipotoxicity, stressed and/or hepatocytes necrosis, are able to 
release the damage-associated molecular patterns (DAMPs), which can act on various 
immune cells in the liver starting a homeostatic response to repair tissue injury. Even so, the 
persistence of these signals can induce an excessive reaction resulting in a full inflammatory 
response with tissue inflammation and excessive scarring and leading to advanced fibrosis 
and finally to cirrhosis (Arrese M 2016).  
There are different type of cells involved in the inflammatory response during NAFLD 
progression (Arrese M 2016): 
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 The Kupffer cells (KCs), resident macrophages of the liver, located in the hepatic 
sinusoids, the portal tract and hepatic lymph nodes. This cell type derives from 
circulating monocytes and represents around 15 % of the liver cells, being the largest 
tissue-specific reservoir of macrophages in the body. The activations of KC, resulting in 
the production of proinflammatory cytokines and chemokines such as TNF-a, IL-1b, IL-
12, IL-13, IL-10, IL-4. This is a key step to trigger local inflammation and to promote 
additional hepatocyte cell injury, leading to the release of DAMPs. Moreover, some of 
these cytokines have overlapping proinflammatory and profibrotic properties, 
contributing to the chemotaxis of inflammatory cells and activation of HSC. 
 Dendritic cells (DCs) are tolerogenic immune cells located around the central veins and 
portal tracts that collectively represent a small fraction of non-parenchymal liver cells 
and mainly originate in the bone marrow. DC may act as antigen presenting cells as 
well as in apoptotic cell clearance and removal of necrotic debris. Recent evidence 
showed that DC rapidly infiltrate the liver, exhibiting an activated immune phenotype 
expressing increased levels of IL-6, TNF-α. 
 Neutrophil accumulation is one of the main features of NASH, and it is thought that this 
cell type critically contributes to hepatocellular damage in this setting as it can 
exacerbate the ongoing inflammatory state by contributing to macrophage recruitment 
and through interaction with antigen-presenting cells. 
 Natural Killer cells (NKs) are lymphoid cells that play a role in linking the innate and 
adaptive immune responses within the liver. Different studies have been shown that NK 
cells may be activated in NASH in connection with elevated levels of several NK cell-
activating cytokines (e.g., IL-12, interferon-c and IL-18) and ligands. Natural Killer T 
cells (NKTs) comprise a unique immune cell subtype that expresses specific NK cell 
surface receptors as well as an antigen receptor (TCR) characteristic of conventional T 
cells. They mainly reside in the sinusoids providing intravascular immune surveillance. 
1.1.4 Fibrosis mechanism 
In NAFLD, fibrosis takes on a characteristic pattern. All cellular responses during and 
after these double hits, are converged to activate the hepatic stellate cells (HSCs) and this 
activation is the responsible of collagen deposition resulting in increased fibrosis. 
The pathways of HSC stimulation include signals that promote activation and those 
that play a part in perpetuation: 
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 Activation is stimulated by soluble stimuli such as ROS, apoptotic bodies, 
lipopolysaccharides (LPS) and paracrine stimuli from neighboring cell types including 
hepatic macrophages (Kupffer cells), sinusoidal endothelium and hepatocytes;  
 Perpetuation is stimulated by fibrogenesis itself, proliferation, altered matrix 
degradation, chemotaxis and contribution of the innate immunity (natural killer cells, 
dendritic cells, Toll-like receptor). 
Resolution of hepatic fibrosis, which occurs following clearance of the primary liver 
disease, leads to loss of activated HSCs, either through apoptosis, senescence or reversion of 
activated cells to a more quiescent phenotype (Friedman SL, Evolving challenges in hepatic 
fibrosis 2010). 
The analysis of fibrogenesis are important complements to tests the disease 
progression. One of the best markers of HSC activation in liver sections is the α-smooth 
muscle actin (αSMA), the more sensitive indicator of the rate of fibrogenesis and risk of 
clinical complications. αSMA is an actin isoform that is normally confided to vascular smooth 
muscle cells, but is also expressed in healing wounds and fibro-contractive lesions (Wang J 
2005). Additional previous studies demonstrated that activation and survival of HSCs were 
closely associated with activation of NFκB and inhibition of its activities is controlled by the 
activation of PPARγ. These studies suggested that inhibition of NFκB activation might be a 
potential strategy for prevention and/or treatment of hepatic fibrogenesis (Hellerbrand C 
1998) (Lee KS 1995).  
 
 
Figure 4. HSC transdifferentiation during hepatic fibrosis progression. 
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1.2 Histological features and disease diagnosis  
The principal histological features of NAFLD (Figure 5) is hepatocellular steatosis and 
steatosis in more than 5% of hepatocytes is required for the diagnosis of NAFLD (Takahashi 
Y 2014). Liver steatosis is divided into: 
 macrovesicular steatosis: a single large or smaller well-defined fat droplets in 
hepatocytes cytoplasm, moving the nucleus to the periphery. Steatosis in NAFLD is 
usually macrovesicular; 
 microvesicular steatosis: tiny lipid droplets in the hepatocytes cytoplasm and the 
nucleus centrally in the cell.  
Hepatocellular injury during the disease progression is characterized by ballooning, enlarged 
hepatocytes characterized as swollen hepatocytes with rarefied cytoplasm. Fat droplets may 
be observed in ballooned hepatocytes in Haematoxylin and Eosin staining. Hepatocellular 
ballooning is believed to result from alteration of the intermediate filament cytoskeleton. In 
ballooned hepatocytes, the two hepatocyte keratins cytokeratins 8 and 18 are disrupted and no 
longer present throughout the cytoplasm; instead, they are dispersed to the periphery. 
 
Figure 5. Haematoxylin and Eosin staining (20X) in a 8μm cryosections liver of NAFLD mouse model. 
Necroinflammatory foci (black arrow), macrovesicular (green arrow) and microvesicular (blue arrow) are 
distributed in the hepatic lobule.  
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Intralobular inflammation is also present and it is usually mild, and consists of a mixed 
inflammatory cell infiltrate (lymphocytes, neutrophils, and Kupffer cells). Scattered lobular 
microgranulomas (sinusoidal Kupffer cell aggregates) and lipogranulomas (consisting of fat 
droplets as well as admixtures of inflammatory cells and collagen) are also often observed in 
NASH. Portal inflammation in NAFLD/NASH is usually absent or mild, and consists mainly 
of lymphocytes. Chronic portal inflammation (greater than mild) has been associated with the 
amount and location of steatosis, ballooning, and advanced fibrosis. Therefore, greater than 
mild chronic portal inflammation in untreated NAFLD could be considered a marker of 
advanced disease. 
Another important histological feature is the fibrosis. The characteristic pattern of 
fibrosis in NASH is perisinusoidal/pericellular fibrosis and Masson trichrome staining can be 
useful to evaluate fibrosis (Figure 6). In early lesion, fibrosis begins as a delicate 
perisinusoidal deposition of collagen fibers. In more advanced lesions, collagen fibers may 
encircle hepatocytes. Pericellular fibrosis can progress without the development of any 
appreciable periportal fibrosis for a long time, but commonly, periportal fibrosis may develop. 
Fibrosis in NAFLD is usually observed with an active necroinflammatory reaction; however, 
fibrosis without active lesions can also occur, and prior episodes of steatohepatitis are 
suggested in such cases. 
 
Figure 6. Masson Goldner trichrome staining (20X) in a 8μm cryosections liver of NAFLD mouse 
model. 
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In the 1999, Brunt and colleague classified all of these histological features (J. C. 
Brunt EM 1999). They proposed to classify the necroinflammatory grades of NASH as: grade 
1 (mild), grade 2 (moderate), and grade 3 (severe) based on the degree of hepatocellular 
steatosis, ballooning and disarray, and inflammation (intralobular and portal). Simultaneously, 
they proposed a scoring system for staging based on the location and extent of fibrosis: stage 
1, zone 3 perisinusoidal fibrosis; stage 2, portal fibrosis with the abovementioned stage 1; 
stage 3, bridging fibrosis in addition to stage 2; and stage 4, cirrhosis. Then, the NASH 
Clinical Research Network (NASH CRN) subclassified stage 1 into 3 categories: stage 1A, 
mild perisinusoidal fibrosis in zone 3; stage 1B, moderate perisinusoidal fibrosis in zone 3; 
and stage 1C, only portal/periportal fibrosis (Kleiner DE 2005). The NASH CRN designed 
the NAFLD activity score (NAS) for use in clinical research. This score can also be used for 
the full spectrum of NAFLD, including simple steatosis. The score is calculated as the 
unweighted sum of the scores for steatosis (0-3), lobular inflammation (0-3), and ballooning 
(0-2), and ranges from 0 to 8 (Table 1). 
 
ITEM DEFINITION SCORE 
Steatosis < 5% 0 
 5 % - 33 % 1 
 > 33 % - 66 % 2 
 > 66 % 3 
Lobular inflammation No foci 0 
 < 2 foci per 200X field 1 
 2-4 foci per 200X field  2 
 > 4 foci per 200X field 3 
Ballooning None 0 
 Few balloon cells 1 
 Prominent ballooning 2 
 
Table 1. Score for histological evaluation of nonalcoholic fatty liver disease components (Adapted from 
Takahashi Y, 2014). 
 
Recently, a new definition based on the SAF score, which does not sub-classify 
patients with NAFLD based on NASH, has been proposed (Bedossa P 2014). The SAF score 
assesses three variables: S = steatosis, A = activity, F = fibrosis and steatosis is classified on a 
scale of 0 to 3 (S0: <5%, S1: 5–33%, S2: 34–66%, S3: >67%). However, this scoring system 
has been shown to decrease intra-observer variation among pathologists.  
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The diagnosis of NAFLD requires that there are evidence of steatosis either by 
imaging or histology and that there are no secondary causes of steatosis, such as increased 
alcohol consumption, viral hepatitis, use of steroid medications or other causes. Steatosis can 
be diagnosed either using invasive and/or non-invasive technique. Non-invasive technique 
includes imaging techniques such as ultrasound or proton magnetic resonance spectroscopy 
(
1
H-MRS). Steatosis on ultrasound and/or proton magnetic resonance spectroscopy does not, 
however, exclude NASH, as they merely quantify steatosis. Invasive technique includes liver 
biopsy, the gold standard for diagnosis of NAFLD. Histologically, NAFLD encompasses any 
degree of steatosis alone or steatosis with lobular inflammation but without ballooning. 
NASH can only be diagnosed by liver biopsy. The presence of ballooning injury is the key to 
the diagnosis. Ballooning degeneration is a form of hepatocyte cell death where the cells 
increase in cell size (balloon). Steatosis and inflammation can be observed to any degree. 
Fibrosis is not required to make the diagnosis of NASH but is often present (Yki-Järvinen H 
2016).  
 
1.3 Cardiovascular complications 
Liver fat could be an important ectopic fat depot that confers additional risk over other 
visceral fat depots. One of the most important mortality and morbidity reasons of NAFLD are 
cardiovascular events. Multiple pathogenetic conditions contribute to the development of 
cardiovascular diseases (CVD). 
The Framingham Heart Study, initiated in 1948 in response to the rapidly increasing 
incidence of cardiovascular-related death, is the longest running prospective cohort study in 
the USA. Through over 65 years of discovery, the Framingham Heart Study has contributed 
to understand obesity, type 2 diabetes mellitus and prediabetes mellitus, the metabolic 
syndrome and NAFLD, and to how these conditions relate to our overall and cardiovascular-
related mortality (Long MT 2016). Recent results, from the Framingham Heart Study (Ma J 
2016), revealed that there was a significant association between NAFLD and CVD 
independently from many other metabolic diseases. NAFLD, not only is a marker of CVD 
and cardiac function abnormalities but also might be involved in their pathogenesis, possibly 
through the systemic release of several pathogenic mediators from the steatotic and inflamed 
liver and other inflammatory cytochines.  
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Figure 7. Patients with NAFLD have many CVD risk factors and the typical traits of the metabolic 
syndrome (Adapted from Lonardo A 2016). 
As shown in Figure 7, patients with NAFLD have a many of traditional and non-
traditional risk factors for CVD. However, several CVD risk factors associated to the 
metabolic syndrome are common in patients with NAFLD so it is not clear if this increased 
CVD risk in patients with NAFLD might be itself a mediator of atherosclerosis (Lonardo A 
2016).  
In the same way as the liver, cardiac lipotoxicity is associated with increasing ROS 
production, which leads to damage and death of myocardiocytes. Indeed, in the healthy heart, 
contractile function depends on the production of intracellular ATP derived primarily from a 
balance between fatty acids and carbohydrate oxidation. This dynamic use of fatty acids and 
glucose for energy production is largely a result of fluctuations in plasma fatty acids 
availability and the resulting changes in fatty acids entry into the cardiac. Immediately 
following uptake, fatty acids are converted into long-chain acyl-CoA esters that can be used to 
form acylcarnitines for transport into mitochondria. Once inside the mitochondria, the re-
formed acyl-CoA esters undergo β-oxidation to produce acetyl-CoA that, upon entering into 
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the tricarboxylic acid (TCA) cycle, undergoes further metabolism to provide the energy for 
ATP production (Brindley DN 2010). Although the healthy heart relies normally on fatty 
acids oxidation for its predominant energy supply, an overreliance on fatty acids compared 
with glucose for energy production has been associated with ventricular dysfunction (Brindley 
DN 2010). Increased fatty acids uptake (for example in diabetes condition) favours the 
oxidation of fatty acids rather than glucose (especially when combined with insulin 
resistance). If fatty acids supply exceeds the capacity for fatty acids oxidation, then the excess 
fatty acids are incorporated into triglycerides, resulting in cardiac steatosis. As in the liver, β-
oxidation of long-chain fatty acids can also release electrons to form ROS and may induct of 
oxidative stress (Mellor KM 2010). 
The concomitance of liver and myocardial injury in patients with NAFLD and the 
probably common molecular pathways of both damages are encouraging therapies to improve 
liver histology and to control myocardial damage. 
 
1.4 Epidemiology 
In the global increases of obesity and diabetes in western countries, NAFLD 
represents the most common cause of liver dysfunction. However, the lack of sensitivity and 
specificity of the test used for the diagnosis limited the correct estimates of prevalence (Bhala 
N 2013). All risk factor of CVD, such as insulin resistance and/or type 2 diabetes, 
dyslipidemia, hypertriglyceridemia and hypertension characterized the majority of NAFLD 
patients. In fact, prevalence of NAFLD has been reported in over 76% of type 2 diabetics and 
over 90% of severely obese patients undergoing bariatric surgery. Given the common risk 
factors between NAFLD and CVD, cardiac-related death is one of the leading causes of death 
for NAFLD patients. It is alarming that the prevalence of NAFLD worldwide is thought to be 
on the rise. The prevalence of NAFLD in the Europe is reported to be between 10% and 30%, 
with similar rates reported from United States and Asia as reported in Table 2. (Younossi ZM 
2016). 
REGION  PREVALENCE (%) 
Africa  13.48 
Asia  27.37 
Europe  23.71 
Middle East  31.79 
North America  24.13 
South America  30.45 
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Table 2. NAFLD Prevalence Stratified by Region and Mean Age (Adapted from Younossi ZM, 2016). 
 
Table 2, clearly indicates that the prevalence of NAFLD increases with age. However, very 
recent evidence suggested that NAFLD in children is becoming a major health concern. 
Remarkably, the overall prevalence of NAFLD in children has reached approximately 10%, 
including up to 17% in teenagers and 40%-70% among obese children. While often benign 
and self-limiting, steatosis can progress with hepatocyte injury into non-alcoholic 
steatohepatitis (NASH) in 3%-5% of patients. Obesity, hypertension, and other components of 
metabolic syndrome, including steatosis and severe liver damage has been associated with the 
progressively increased intake of added sweeteners in the last few decades. When compared 
with their obese counterparts without NAFLD, the obese children with NAFLD consume 
more carbohydrates. The epidemics of pediatric obesity and obesity related liver disease 
(NAFLD and NASH) represents a serious problem. Increasing evidence indicates that 
affected children are at risk of significant progressive hepatopathy if inflammation and/or 
advanced fibrosis are already present (Clemente MG 2016).  
 
1.5 Treatments 
Adult and pediatric NAFLD does not have a globally efficacious treatment. Lifestyle 
interventions (i.e. dieting and exercise) represent the pillar treatment, while effective 
interventions in adults and children are challenging due to a lack of compliance (Clemente 
MG 2016). In addition to the physical training and diet control, there is no consensus on the 
most effective pharmacological therapies for NAFLD/NASH caused by the complex 
pathophysiology. The common approach involves the therapy of the disease complications, 
such as hepatic fat accumulation, insulin resistance, inflammation, and fibrosis. For example, 
pioglitazone and metformin, common treatments for glucose intolerance, can enhance insulin 
sensitivity in patients with NAFLD/NASH; however, other histological features such as 
fibrosis, are not significantly treated. Pirfenidone, a therapeutic agent used for fibrosis, can 
reduce the serum alanine aminotransferase and aspartate aminotransferase concentrations and 
MEAN AGE  PREVALENCE (%) 
30-39  22.43 
40-49  26.53 
50-59  27.40 
60-69  28.90 
70-79  33.99 
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has anti-fibrotic and anti-inflammatory properties that help to reverse liver injury (Chen G 
2016) (P. L. Del Ben M 2014). 
NAFLD, a major challenge to healthcare systems worldwide, has no medications 
approved by the United States Food and Drug Administration. As mentioned above, most 
people with fatty liver do not develop severe liver disease but have an increased chance of 
developing cardiovascular diseases. For these reasons, the treatment of NAFLD patients 
should be based on a global approach, not only addressing the treatment of insulin resistance 
and metabolic syndrome, but also including strategies focused on reducing oxidative stress, 
dyslipidaemia and cardiovascular risk. So, next to the many therapeutic strategies approaches, 
several types of nutraceuticals have been suggested for the treatment of NAFLD and NASH, 
the most promising of which are those with anti-inflammatory and antioxidant effects (P. L. 
Del Ben M 2016). In this context, nutraceuticals may have an important role in NAFLD and 
cardiovascular risk treatment, in combination with the conventional medicament. 
 
1.6 Nutraceutical compounds 
1.6.1 History  
The term "nutraceutical" was coined from "nutrition" and "pharmaceutical" in 1989 by 
Stephen L. DeFelice, MD, founder and chairman of the Foundation for Innovation in 
Medicine (FIM). According to DeFelice, nutraceutical can be defined as "a food (or part of a 
food) that provides medical or health benefits, including the prevention and/or treatment of a 
disease" (Brover V 1998). In Italy, dietary supplements are defined (Directive 2002/46/EC, 
implemented by Decreto Legislativo del 21 May 2004, n. 169) as "foodstuffs to supplement 
the common diet and which are concentrated sources of substances nutrients, such as vitamins 
and minerals, or other substances with a nutritional or physiological effect, in particular, but 
not limited to, amino acids, essential fatty acids, fiber and plant-derived extracts, alone or in 
combination, in unit dose form" (Ministero della Salute s.d.). 
Dietary supplements are used by a substantial part of the general population, and the 
available evidence suggests that the rate of use is even higher among people and patients and 
the pattern of use varies between type of diet (i.e. vegan) or/and type of disease. 
1.6.2 L-Carnitine 
L-carnitine (LCARN) was discovered in 1905 as a constituent of muscle tissue 
(Gulewitsch and Krimberg, 1905; Kutscher, 1905). It owes its name to the high concentration 
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with which it occurs in meat and its chemical structure was elucidated some 20 years later 
(Figure 8). After the early 1940s its stereospecificity was clarified and in the 1960s, 
researcher described the antiomeric forms occurs in the body. The biological activity of 
LCARN, named vitamin T, was firstly described as essential nutritional factors in mealworms 
larvae, which are popular with aquaculturists, as fish food. The “T” in this abbreviation stands 
for the Latin name for the mealworm, Tenebrio molitor. Mealworm larvae growing in a state 
of LCARN deficiency accumulate excessive amounts of fat in their cells and yet seem to die 
of starvation. This suggested that LCARN might play a role in the oxidation of fat. The 
function of LCARN in mammals, however, remained a mystery for a long time. In 1955 Fritz 
and colleague, discovered that adding LCARN to muscle extracts stimulates the oxidation of 
palmitate. This observation led to the discovery of the mitochondrial carrier function of 
LCARN and its important role in the burning of free fatty acids in 1962 by Bremer (Wolf G 
2006).  
Many further biological functions of LCARN have become known since then. The 
fatty acids with chain lengths of 12 or fewer carbons enter mitochondria without the help of 
membrane transporters. Those with 14 or more carbons, which constitute the majority of the 
FFAs obtained in the diet or released from adipose tissue, cannot pass directly through the 
mitochondrial membranes—they must first undergo the three enzymatic reactions of the 
carnitine shuttle (Nelson DL Sixth Edition).  
 
Figure 8. L-carnitine, (β-hydroxy-γ-trimethyl-aminobutyrate). In aqueous solution LCARN, being a 
zwitterion, is freely soluble in water as its ionisable groups (COO
-
 and N
+
(CH3)3) are over 90 % dissociated at a 
physiological pH (~7.4). In red, the binding site for acyl residues. 
The hydroxyl group at the C2 location of LCARN is virtually undissociated in 
solution, but is of great physiological significance because it determines one of its functions 
in the body. The β-hydroxyl group of LCARN reacts with activated fatty acids (acyl-CoA 
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compounds) and, catalysed by L-carnitine acyltransferases (CAT), forms energy-rich acetyl-
L-carnitine in the process. This occurs in principle by the following reaction: 
 
 
This reaction is reversible, as required, depending on cellular localisation (intra- and extra-
mitochondrial) and chain length of the acyl residues. It is catalysed by various L-carnitine 
acyltransferases.  
LCARN is absorbed actively and passively in the intestine. The transport capacity is 
low when compared with that for glucose and amino acids. LCARN is presumably partially 
esterified in the intestine before being released into the blood. The liver receives some 
LCARN from the portal blood and releases it with a time delay back into the blood. The liver 
with the bile also releases LCARN esters (enterohepatic cycle). LCARN and LCARN esters 
are readily filterable in the renal glomeruli. In animals with a normal LCARN status, more 
than 98% of free LCARN is absorbed via the tubules. The absorption of LCARN esters is less 
efficient. However, tubular absorption can be modified depending on dietary supply, 
requirement (Wolf G 2006).  
1.6.3 L-Carnitine and NAFLD 
In recent years, the effects of nutraceuticals on NAFLD have received increasing 
attention and several types of these agents have been suggested for the treatment of 
NAFLD/NASH. For some of them, a number of clinical trials highlighted an improvement in 
liver function tests and a possible positive influence on liver histology (Somi MH 2014) 
(Malaguarnera M 2010). Very recently in vivo studies have been indicated the oxidative 
mechanism as an important therapeutic intervention strategy for NAFLD (Li W 2016). It has 
been shown that LCARN administration can ameliorate or prevent liver damage of various 
aetiologies reinforcing the hepatic mitochondria β-oxidation and the activity of the key ROS-
scavenging antioxidant enzymes without an increase in oxidative stress (Ishikawa H 2014). 
Several nutraceutical supplements have shown promising results, especially those 
containing antioxidants and polyphenols. However, present information derives mostly from 
small trials with considerable heterogeneity with respect to inclusion criteria, sample size, 
type of experimental interventions and duration. A Cochrane review in 2007 (Lirussi F 2007), 
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reported that there was insufficient data to either support or refute the use of antioxidant 
supplements for patients with NAFLD and it may be advisable to carry out large prospective 
randomised clinical trials on this topic (Lirussi F 2007). In 2016, there are still insufficient 
data to either support or refute the use of nutraceuticals for subjects with NAFLD. Further 
randomized controlled studies, with histological changes as an outcome measure, are needed. 
1.6.4 L-Carnitine and cardiovascular disease 
Carnitine deficiency has even been associated with heart failure and supplementation 
has been recommended in the treatment of CVD and in selected patients with acute 
myocardial infarction (Gaby AR 2010). In rodent studies, LCARN improves myocardial 
ischaemia/reperfusion injury via stimulation of glucose oxidation (Broderick TL 1996).  
A well-publicized study by Koeth and collaborators. (Koeth RA 2013), indicated that 
intestinal microbiota can metabolize carnitine to trimethylamine, which is then oxidized in the 
liver to the proatherogenic trimethylamine-N-oxide (TMAO). In a mouse model, chronic 
LCARN therapy altered cecal microbial composition, enhanced synthesis of TMAO, and 
increased atherosclerosis, but this did not occur if antibiotics concurrently suppressed 
intestinal microbiota. Following this work, nutrition scientists have argued the merits and 
limitations of the study, resulting in the current state of discord (L. G. Ussher JR 2013). Some 
investigators have suggested that reducing dietary LCARN and choline is the simplest and 
safest means to control TMAO levels, and that the development of novel therapeutics 
targeting the gut microbiome may lead to improved CVD outcomes (Mendelsohn AR 2013). 
Ussher and collaborators (L. G. Ussher JR 2013) noted that in the Koeth study (Koeth RA 
2013), LCARN was delivered concurrently with red meat, confounding the experiment and 
those experimental doses of LCARN were up to 1000 times higher than a 220gr steak. In 
addition, LCARN and choline are significant contributors to bile secretions by mass and were 
likely reabsorbed prior to reaching the cecum/colon for bacterial conversion to TMAO, 
further confounding biological interpretation  
Nevertheless, LCARN has also been recognized as a nutritional supplement in 
cardiovascular disease and it is currently used as an adjunctive therapy in various heart 
conditions with promising results (Johri AM 2014) (Strilakou AA 2013).  
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1.7 Mouse models of NASH 
As thoroughly described, the development and progression of NAFLD to NASH 
represents a complex pathophysiological process. To date, no single animal model has 
encompassed the full spectrum of human disease progression, but they can imitate particular 
characteristics of human disease; for these reasons, the appropriate animal selection is very 
important. 
The animal models of NASH could be divided into (Habbard L 2011): 
 Dietary-based animal models: MCD diet, high fat, cholesterol and cholate, fructose. 
 Genetic models: adipocyte-mediated inflammation, adiponectin, regulation of Wnt 
signalling, high‑fat‑diet‑promoted adipocyte apoptosis, linking adipose inflammation 
and steatosis. 
 Additional causes of fatty liver: cholesterol, innate immunity, steatotic polymorphisms 
and mouse models. 
The primary driver of NAFLD is over-nutrition and a sedentary lifestyle leading to 
increased weight and, ultimately, obesity. The majority of animal models focus on providing a 
diet that cause liver damage. The model used most often is actually nutrient deficient. The 
methionine and choline deficient (MCD) diet is high in sucrose and fat (40% sucrose, 10% 
fat), but lacks methionine and choline, which are essential for hepatic β-oxidation and the 
production of VLDL. This results in the accumulation of intrahepatic lipid and decreased 
VLDL synthesis. Mice fed the MCD diet lose weight (up to 40% in 10 weeks). With a loss of 
white adipose tissue, the liver decreases proportionally in size, develops prominent pericentral 
steatosis, subsequent necroinflammation and fibrosis, resembles that seen in human NASH. 
MCD fed mice exhibit increased inflammation by way of activated macrophage infiltration 
into the liver, the activation of NFκB and concomitant increases in interleukin 6, transforming 
growth factor β and tumor necrosis factor (Habbard L 2011). The main advantages of the 
MCD diet are that it is widely available and replicates NASH histological phenotype within a 
relatively shorter feeding time than other dietary models of NASH. 
The severity of NASH in mice fed the MCD diet depends on rodent gender and strain. 
Kirsch and colleague (Kirsch R 2003) analysed male and female C57/BL6 mice fed the MCD 
diet with respect to liver histology (steatosis and necroinflammation), ultrastructure and lipid 
biochemistry and compared with Wistar rats, the most susceptible rat strain. In this study, 
male C57/BL6 mice showed ultrastructural evidence of hepatocyte injury, including profound 
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mitochondrial enlargement, blebbing of nuclear membranes, and dissociation of rough 
endoplasmic reticulum from mitochondria. Mitochondrial injury in these animals may be a 
result of oxidative stress and consequent lipid peroxidation of mitochondrial membranes. 
Mitochondrial injury activates hepatocyte apoptotic mechanisms and results in hepatocyte 
necrosis, a prominent feature in male C57/BL6 mice. The increased lipid peroxidation in these 
mice compared with Wistar rats may, explain differences in necroinflammation in these 
animals. In conclusion, male C57/BL6 mice develop the histological features that most 
closely resemble those seen in human NASH. 
Another important characteristic in mice fed a MCD diet, is the development of 
hepatic steatosis characterized by increased free fatty acid (FFA) and triglyceride levels as 
well as expression of αSMA as marker of activation of HSC and the consequent fibrosis 
mechanism (Lee SJ 2015). 
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2. PRELIMINARY in vitro STUDY 
As mentioned, NAFLD, a major challenge to healthcare systems worldwide, has no 
medications approved by the United States Food and Drug Administration. So, next to the 
many therapeutic strategies approaches, several types of nutraceuticals have been suggested 
for the treatment of NAFLD and NASH, the most promising of which are those with anti-
inflammatory and antioxidant effects (P. L. Del Ben M 2016). In this context, nutraceuticals 
may have an important role in NAFLD in combination with the conventional medicament. 
In our previous work (Montesano A Under Submission), we analyzed the role of 
LCARN in liver steatosis condition in an in vitro model of fructose‑induced lipid 
accumulation. The effects of LCARN supplementation on HepG2 cells fat deposition, 
antioxidative response and mitochondrial pathway activation were studied with or without 
fructose overload (Zhao L 2016). Research results of the last several years, confirmed the 
initial assumption that HepG2 cells are an excellent tool to detect metabolic properties of 
biological compounds (Knasmüller S1 2004) and expresses most of the marker proteins of 
human hepatocytes. Our data showed that LCARN supplementation reduced HepG2 
intracellular lipid accumulation induced by fructose. Moreover, LCARN treatment stimulated 
AMPK activation trough the increase of CaMKII stimulation. Overload of lipids in HepG2 
cells, induces the abundant production of ROS that contributes to organelle toxicity and an 
increase in lipid peroxidation. In our work, LCARN decreased ROS production. Taken 
together all of these data confirmed the potential protective role of LCARN supplementation. 
Our preliminary expertise in the nutraceutical research field and the experimental 
evidence obtained in an in vitro model of NAFLD, endorses us to demonstrate the role of 
nutraceutical supplementation in an in vivo mouse model of NAFLD. 
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3. AIM OF THE STUDY 
Non-Alcoholic Fatty Liver Disease has no approved medications and innovative 
therapeutic strategies are needed. Nutraceuticals are defined as a new frontier between drugs 
and food. Due to the complex pathogenesis and complications of the NAFLD, several types of 
these agents have been suggested for the treatment and the oxidative mechanism is resulted 
the key target. Malaguernera and collaborators (Malaguarnera M 2010) demonstrated that 
LCARN supplementation is useful for improving liver function and histological 
manifestations of NAFLD progression. However, the mechanisms whereby LCARN could 
mediate its action on liver function and NAFLD complications is still unclear.  
The aim of the study was to investigate the nutraceutical effects of LCARN 
supplementation on liver fat deposition, oxidative stress and fibrosis development mechanism 
in a mice model of steatohepatitis induced by a methionine-choline deficient diet (MCD diet). 
Liver fat could be an important ectopic fat depot that confers additional risk over other 
visceral fat depots. One of the most important mortality and morbidity reasons of NAFLD are 
cardiovascular events. For this reason, in the same in vivo model we also analyzed the shared 
role of LCARN in cardiac tissue. 
 
4.  EXPERIMENTAL PROTOCOL 
As reported in literature (Habbard L 2011) (Kirsch R 2003), animals fed the MCD diet 
lost weight, led to steatohepatitis and best approximated the histological features of human 
NASH. After two weeks of acclimation, ten-week-old male C57BL/6 mice were divided into 
three experimental groups: one group (n=10) were fed with 120g/week of normal diet 
(CONTR) and two groups (n=10 each group) with 120g/week of MCD diet (MCDD) for nr. 6 
weeks. After the first 3 weeks, one of the MCDD food group was enriched with 200mg/kg/die 
oral LCARN (MCDD+LCARN) until the end of the experiments. All animals were sacrificed 
at the end of the experiments (nr. 6 weeks of diet) as reported in Figure 9.  
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Figure 9. Experimental protocol. 
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5. MATERIALS AND METHODS 
This study was conducted in compliance with approved institutional animal care of the 
University of Milan. 
 
5.1 Materials 
Reagents were purchased from Sigma Chemical Co. (Saint Louis, MO, USA). Primary 
antibodies against AMPKα 1/2 (sc-25792), CaMKII (sc-9035), pCaMKIIα (sc-12886-R), 
ERK2 (sc-154), pERK 1/2 (sc-7383), GAPDH (sc-25778), NFκBp65 (sc-109), PPARγ (sc-
7196), αSMA (sc-53142), peroxidase-conjugated secondary antibodies for Western blot 
analysis, and rhodamine-conjugated antibodies for immunofluorescence analysis were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary antibodies 
STAT3 (#9132) and phospo-STAT3 (#9131) were purchased from Cell Signaling Technology 
(Danvers, MA, USA). 
Cell ROX® Oxidative Stress Reagents Kit (C10443) from Thermo Fisher Scientific, 
Life Technologies Italia (Monza-Italy). 
Masson-Goldner staining kit (100485), Weigert’s iron hematoxylin kit (115973), 
Entellan®Neo (107961) from Merck Millipore, Merck KGaA (Darmstadt, Germany). 
Mayer’s Hematoxylin Solution (MHS16-500ML), Eosin Y Solution 0,5% acqueous 
(HT110216-500ML), Scott’s Tap Water Substitute Concentrate (S5134),  Oil Red O solution 
0.5% in isopropanol (O1391-500ML),Glycerol gelatin aqueous slide mounting  (GG1-15ML), 
Formalin Solution 10% (HT501128-4L) and Bouin’s Solution (HT10132-1L) from Sigma-
Aldrich® (Sigma-Aldrich Co. LLC.). 
 
5.2 Animal Studies 
Animals and experimental protocol  
Male C57BL/6 mice (n=30), purchased from Charles River Laboratories (Boston, MA, 
USA), were used for the study at 10 weeks of age. All animals were kept on a 12 h/12 h 
light/dark cycle with unlimited access to standard rodent chow food and water. Mice were 
divided into three paired groups: one group (n=10) were feed with 120g/week of normal diet 
(CONTR) and two groups (n=10 each group) with 120g/week of MCD diet (ssniff® EF R/M 
Induction of fatty liver – Ssniff Spezialdiäten GmbH) (MCDD) for nr. 3 weeks. Food of one 
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of the MCDD group after the first 3 weeks, was enriched with 200mg/kg/die oral L-carnitine 
(MCDD-LCARN) for other nr. 3 weeks and all animals were sacrificed at the end of the 
experiment. As reported in literature (Hebbard L 2011) (Kirsch R 2003), mice fed the MCD 
diet lose weight and promoted liver damage.  
 
LCARN Treatment 
LCARN was added to the drinking water at dose of 200 mg/kg body weight per day, 
for 3 weeks. Control mice received water without LCARN. In our pilot study, water and 
LCARN were changed daily and the dose adjusted to weight gain each week.  
 
5.3 Experimental Procedures 
Protein extracts 
Liver and heart protein extracts, were obtained from homogenized mouse tissues by 
using the following lysis buffer containing: 50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 1 mM sodium orthovanadate (Na3VO4), 1 mM EDTA, 1 mM PMSF, 1 mg/mL 
aprotinin, 1 mg/mL leupeptin, and 1 mg/mL pepstatin and shaked for 1 h at 4°C. Detergent-
insoluble material was removed from the cell suspension by centrifugation at 12.000 x g for 
30 min at 4°C. Protein contents were quantified using Bradford method. 
Western Blot Analysis 
Aliquots of quantified 30 μg supernatant proteins, were resolved on SDS-PAGE gel 
and transferred onto nitrocellulose membrane (Protran, Whatman Schleicher & Schuell). The 
membranes were incubated with specific primary antibodies and then with HRP conjugated 
anti-species-specific secondary antibodies. To confirm equal protein loading per sample, we 
used antibody anti-GADPH. Quantitative measurement of immunoreactive bands intensities, 
visualized by an enhanced chemiluminescence method (Amersham Pharmacia Biotech, 
Piscataway, NJ, USA), was performed by densitometric analysis using the Scion Image 
software (Scion Corporation, Frederick, MD, USA). Data were then converted into fold-
changes (FC) of the controls. 
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Histopathologic Analysis 
At the end of the study, animals were ether anesthetized, killed, and their livers and 
heart were removed, weighed and sampled for histological assessment. Additional samples 
were snap frozen in liquid nitrogen for later analysis of liver lipid levels and lipid 
peroxidation.  
Liver and heart 8 μm frozen cryosections, were examined with different staining 
technique. Tissue sections were examined with Hematoxilin and Eosin (HE) (Sigma) staining 
according to the manufacturer’s instruction. Images were acquired by phase contrast 
microscopy and lipid droplets area was calculated with Image J software. 
Staining of intracellular lipid droplets was performed with Oil Red O (ORO) (Sigma) 
technique according to the manufacturer’s instruction.  
Masson-Goldner (MG) (Merck Millipore) staining method is a trichrome stain that is 
primarily used for imaging connective-tissue structures in organs. Connective tissue is then 
counter stained using light green SF solution manufacturer’s instruction. 
 
Immunofluorescence Analysis 
Liver and heart 8 μm frozen cryosections, were fixed 4% paraformaldehyde for 30 
minutes at room temperature. After that, sections were washed with PBS and permabilized 
with 0.2% Triton X-100. Then were incubated for 30 minutes at room temperature with 10% 
donkey serum. Finally, were immunostained with specific primary and secondary antibodies, 
Rhodamine- or FITC-conjugated, and nuclei were revealed with DAPI staining.  
Cell ROX® Oxidative Stress Reagents are fluorogenic probes designed to reliably 
measure reactive oxygen species (ROS) in tissue. The cell-permeable reagents are non-
fluorescent or very weakly fluorescent while in a reduced state and upon oxidation exhibit 
strong fluorogenic signal. Cell ROX® Orange Reagents are localized in the cytoplasm. This 
staining were performed on CONTR, MCDD and MCDD-LCARN mice liver at the end of 
the experiments. Slides were mounted with Moviol. 
Tissue sections were observed using Nikon Eclipse 50I microscopy and images were 
captured using Nis-Elements D 4.00 software (Nikon Instruments Europe BV, Netherlands). 
Data were displayed and analyzed using Adobe Photoshop CS4. 
Automated quantification on the immunofluorescence signal was performed using 
Image J program (http://imagej.nih.gov/ij/), as described (Montesano A Under Submission). 
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5.4 Statistical Analysis 
All experiments were performed three times. Statistical analysis were performed with 
GraphPad Prism software (GraphPad). Data were presented as the mean ± SD or SEM. 
Multiple comparisons on data sets were performed using t-test, one-way analysis of variance 
(ANOVA), followed by Tukey's post-hoc test. Results were considered significant when 
p≤0.05.  
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6. RESULTS 
Body weight and LCARN supplementation 
There were significant differences in body weight and in food consumption among the 
three groups (Figure 10A and B). A weight reduction was observed in MCDD and 
MCDD+LCARN groups, comparing the beginning and the end of the experiment and the 
MCDD and MCDD+LCARN mice weight were significantly different compared to CONTR 
mice at each week. At week 4 and 5, the MCDD mice eat/weight compared to the CONTR 
were significantly different. 
Water consumption in the three group recorded every day was not influenced by 
LCARN oral supplementation (Figure 10C). 
 
Figure 10. Body weight, food consumption and LCARN supplementation. (A) Body weight of the three 
experimental groups. Every weeks, mice were weighted. (B) Food consumption of the three experimental 
groups. (C) Water consumption and oral LCARN supplementation in MCDD mice group were recorder each 
day. Data are presented as mean ± SEM. Statistical significances: Mice weight by Anova p≤0.0001; Tukey's 
multiple comparisons test *p<0.0001 CONTR vs MCDD and CONTR vs. MCDD+LCARN each week. Mice 
eat/weight by Anova p≤0.0001; Tukey's multiple comparisons test **p=0.0231 CONTR vs MCDD week 4, 
***p=0.0169 CONTR vs MCDD week 5.  L-carnitine oral dose by Anova with no significant differences among 
means.  
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All of the below results were obtained after the mice sacrificed at the end of the 
experiment. 
Liver mass, morphology and histology  
Macroscopically livers from MCDD mice appeared pale and fatty compared with 
controls and mice received LCARN supplementation (Figure 11A).  
The livers of CONTR mice in mass were 14.2% heavier than MCDD group and 13% 
than mice received LCARN supplementation, while the livers of MCDD+LCARN in mass 
were 1.4% heavier than MCDD mice (Table 3). To control the loss of body mass induced by 
the MCD diet, liver mass was expressed as a percentage of body mass (relative liver mass).  
As shown in Figure 11B, the MCDD group developed hepatocyte steatosis and 
ballooning at 6 weeks at HE-staining. Hepatocyte steatosis and ballooning was significantly 
reduced after 3 weeks of LCARN supplementation. Percentage of tissue area containing 
hepatic lipid droplets was significantly lower in the group supplemented with LCARN (Figure 
12). These results were confirmed with ORO-staining technique as shown in Figure 11C. 
 
 
CONTR MCDD 
MCDD+ 
LCARN 
 
Liver mass (g) 
 
1.65 ± 0.21 0.90 ± 0.27 0.94 ± 0.13 
 
Relative liver mass (as % of body mass) 
 
5.46 ± 0.83 4.68 ± 1.19 4.75 ± 0.68 
 
Percentage differences in relative liver mass 
MCDD and MCDD+LCARN vs. CONTR (%) 
 
 14.2 13.0 
 
Percentage differences in relative liver mass 
MCDD vs. MCDD+LCARN (%) 
 
 
1.4 
 
Table 3. Liver mass absolute and relative and percentage differences in relative liver mass resulting 
from the MCD diet at the end of the experiment. Relative liver mass are expressed as a percentage of body mass. 
Data are expressed as a mean ± SD for each group.  
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Figure 11. Liver macroscopic and histological findings at the end of the experiment. (A) Macroscopic 
appearance of livers from mice of the three different groups. (B) HE-stained sections from mice showed 
differences in fatty change (magnification 20X). (C) ORO-stained sections from mice confirmed hepatic lipid 
accumulation (magnification 20X). (D) MG-trichrome stained sections from mice used for the detection of 
fibrotic areas in livers (magnification 20X). 
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Figure 12. Quantification of hepatic lipid droplets area at the end of the experiment. Percentage of 
tissue area containing hepatic lipid droplets was calculated from lipid droplets size from HE-staining sections 
(magnification 20X). Data are presented as mean ± SEM. Statistical significances:  Anova p≤0.0001; Tukey's 
multiple comparisons test ****p<0.0001 CONTR vs. MCDD, CONTR vs. MCDD+LCARN, ***p=0.0005 
MCDD vs. MCDD+LCARN. 
 
As described, fatty acid oxidation is activated and controlled by the AMP-activated 
protein kinase (AMPK). Ca2+/calmodulin-dependent protein kinase II (CaMKII), is an 
upstream kinase in the AMPK cascade (Anderson N 2008). In our previous in vitro work on 
HepG2 cells, the treatment with LCARN stimulates AMPK protein synthesis and 
consequently CaMKII protein levels (Montesano A Under Submission). 
CaMKII level was significantly decrease in MCDD and MCDD+LCARN mice in 
respect of CONTR group. Three-week of LCARN supplementation caused sharp increase of 
CaMKII compared to the MCDD group in immunofluorescence assay (Figure 13A). Different 
results were obtained with the phosphorylated active form of CaMKIIα (pCaMKII) (Figure 13 
B). LCARN supplementation significantly increased pCaMKIIα compared to the MCDD 
group. 
The AMPK level was detected by immunofluorescence assay and western blot 
analysis but we did not obtained sufficient data to show. 
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Figure 13. Level of CaMKII and phosphorylated CaMKII in hepatocytes. A) Representative 
Immunofluorescence assay of total CaMKII content in mice hepatocytes of the three group and relative 
quantification. CaMKII Anova p<0.0001; Tukey's multiple comparisons test ****p<0.0001 CONTR vs MCDD; 
***p=0.0003 CONTR vs. MCDD+LCARN. B) Representative Immunofluorescence assay of phospho CaMKII 
(pCaMKII) content in mice hepatocytes of the three group and relative quantification. pCaMKII Anova 
p<0.0028; Tukey's multiple comparisons test **p<0.0023 CONTR vs MCDD; *p=0.0308 MCDD vs. 
MCDD+LCARN. All data shown are means ± SEM.  
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The hepatic antioxidant effect of LCARN supplementation  
Oxidative stress is induced by reactive oxygen species (ROS) during the progression 
of NAFLD. Recent evidence have identified potential micronutrient antioxidants that may 
reduce the accumulation of ROS and finally ameliorate the disease (Chen G 2016). Animal 
studies have described that mice fed a MCD diet become severely depleted of hepatic anti-
oxidants. By decreasing oxidative defense mechanisms, MCD diet increase oxidant stress, a 
situation that is known to induce inflammation (Li W 2016). 
To verify the antioxidative effect of LCARN supplementation, we quantified the ROS 
level after immunofluorescent assay. As shown in Figure 14, three weeks of MCD diet 
dramatically increased ROS level, while LCARN significantly reduced ROS level in 
MCDD+LCARN group compared to the MCDD group.  
It is also known that MCD diet feeding for two weeks caused a remarkable reduction 
in hepatic ERK1/2 phosphorylation and a progression of the liver injury (Wang Z. 2010). In 
particular, ERK1/2 suppression may be critically involved in the early-stage liver injury and 
during ROS exposure. To test if LCARN supplementation may prevents ERK1/2 suppression 
and alleviates liver injury in MCD-fed mice, we analyzed the phosphorylated active form of 
ERK (pERK) in the liver of the three different mice group. As shown in Figure 14, three-
week of LCARN supplementation increased significantly pERK 1/2 level compared to the 
MCDD group.  
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Figure 14. Quantification of hepatic ROS level. The effect of LCARN supplementation on hepatic ROS 
level in the three mice group. Staining of ROS mice livers and relative quantification. Data shown are means ± 
SEM; Anova p<0.0161; Tukey's multiple comparisons test *p=0.0430 CONTR vs. MCDD, *p=0.0386 MCDD 
vs. MCDD+LCARN. 
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Figure 15. Level of phosphorylated ERK  ½ in hepatocytes. Representative Immunofluorescence assay 
of phospho ERK ½ (pERK 1/2) content in mice hepatocytes of the three group and relative quantification. Data 
are expressed as fold changes (FC) ± SEM. pERK Anova p<0.0026; Tukey's multiple comparisons test 
**p=0.0040 CONTR vs. MCDD, **p=0.0048 MCDD vs. MCDD+LCARN. 
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Activation of hepatic PPARγ plays a critical role in inhibition of NFκB activity by 
LCARN supplementation. 
Transcription factor NFκB has been described as a primary regulator and mediator of 
oxidative stress and it is widely accepted that oxidative stress plays crucial roles in HSCs 
activation during liver injury. Although the causal relationship remains unknown, previous 
studies demonstrated that activation and survival of HSCs were closely associated with the 
activation of NFκB. Furthermore, PPARγ expression was diminished in HSCs as they 
underwent myofibroblastic activation and it was demonstrated that the level of PPARγ was 
reduced during HSCs activation in vitro, whereas NFκB activity were increased (Xu J 2003) 
(Miyahara T 2000).  
Liver protein extracts of the three mice group were prepared for western blot analysis. 
As shown in Figure 16, LCARN supplementation caused a significantly increase of PPARγ 
level and a consequent NFκB p65 decreased compared with the CONTR group. 
 
 
Figure 16. Effect of LCARN supplementation in the control of oxidative stress and fibrosis progression 
at the end of the experiment. Western blot data indicated that LCARN supplementation significantly increased 
the A) PPARγ level resulting in B) decreased NfκB p65 level. Data are expressed as fold changes (FC) ±SD. 
Statistical significances: PPARγ Anova test p≤0.0077; Tukey's multiple comparisons test *p=0.0297 CONTR vs. 
MCDD+LCARN and **p=0.0088 MCDD vs. MCDD+LCARN. NfƙB Anova test p≤0.0001; Tukey's multiple 
comparisons test ****p<0.001 CONTR vs. MCDD+LCARN and CONTR vs. MCDD, ***p=0.0009 MCDD vs. 
MCDD+LCARN. 
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The role of LCARN in the hepatic fibrosis mechanism  
To study if the intracellular fat and oxidative stress were able to induce HSC 
transactivation and fibrosis development, we first analyzed with MG-staining method the 
fibrotic area in the liver of the three groups as shown in Figure 11D. LCARN supplementation 
seemed to delay the fibrosis mechanism progression probably caused by its action on the 
control of the hepatic lipid accumulation. 
In the past few years, several reviews have emphasized the essential role of hepatic 
stellate cell (HSC) activation into myofibroblasts during the pathogenesis of hepatic fibrosis. 
The αSMA protein, marker of HSC activation in liver, is a more sensitive indicator of the rate 
of fibrogenesis and risk of complications (Friedman SL 2010). Recent scientific data indicates 
that MCD diet-induced NASH mice, induced the expression of αSMA protein (Li YH 2016). 
In order to understand the role of LCARN supplementation in liver fibrosis activation 
and progression, we analyzed the αSMA level after immunofluorescent assay. As shown in 
Figure 17 and confirmed in Figure 11D, LCARN supplementation seemed to ameliorated 
HSCs activation and the NASH phenotype of MCD diet-fed mice. Three-week of LCARN 
supplementation caused a significant decrease of αSMA compared to the MCDD group 
(Figure 17).  
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Figure 17. Level of α-SMA in hepatocytes. Representative Immunofluorescence assay of α-SMA 
content in mice hepatocytes of the three group and relative quantification. Data are expressed as fold changes 
(FC) ± SEM. αSMA Anova p<0.0012; Tukey's multiple comparisons test ***p=0.0010 CONTR vs. MCDD, 
*p=0.0206 CONTR vs. MCDD+LCARN, *p=0.0401 MCDD vs. MCDD+LCARN. 
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Heart mass, morphology and histology 
One of the most important mortality and morbidity reasons of NAFLD are CVD 
events. As reported from the Framingham Heart study, there was a significant association 
between NAFLD and subclinical CVD outcomes, independently of many metabolic diseases 
(Fotbolcu H 2016) (Long MT 2016). 
Macroscopically hearts from MCDD mice appeared normal compared with controls 
and mice received LCARN supplementation (Figure 18A).  
To control the loss of body mass induced by the MCD diet, heart mass was expressed 
as a percentage of body mass (relative heart mass). As shown in Table 4, the hearts of 
CONTR mice in mass were 67.4% less heavy than MCDD group and 34.9% than mice 
received LCARN supplementation, while hearts of MCDD+LCARN mice were in mass 
24.1% less heavy relative to MCDD group (Table 4).  
The myocardium of mice fed MCD diet not showed diffuse vacuolar degeneration at 
HE-staining (Figure 18B), and no intracellular accumulation of lipids with ORO-staining 
(Figure 18C); myocardiocytes with abnormal size and altered nuclear morphology were not 
observed.  
 
Table 4. Heart mass absolute and relative and percentage differences in relative heart mass resulting 
from the MCD diet at the end of the experiment. Relative heart mass are expressed as a percentage of body mass. 
Data are expressed as a mean ± SD for each group. 
 
CONTR MCDD 
MCDD+ 
LCARN 
 
Heart mass (g) 
 
0.25 ± 0.01 0.26 ± 0.03 0.22 ± 0.02 
 
Relative heart mass (as % of body mass) 
 
0.83 ± 0.02 1.39 ± 0.17 1.12 ± 0.07 
 
Percentage differences in relative heart mass 
MCDD and MCDD+LCARN vs. CONTR (%) 
 
 - 67.4 - 34.9 
 
Percentage differences in relative heart mass 
MCDD vs. MCDD+LCARN (%) 
 
 
- 24.1 
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Figure 18. Heart macroscopic and histological findings at the end of the experiment. (A) Macroscopic 
appearance of hearts from mice of the three different groups. (B) HE-stained sections from mice showed the 
heart tissue histology (magnification 20X). (C) ORO-stained sections from mice confirmed no lipid 
accumulation (magnification 20X). (D) MG-trichrome stained sections from mice used for the detection of 
fibrotic areas in heart (magnification 20X). 
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The effect of LCARN supplementation in cardiac stress  
Enhanced oxidant stress is an important feature of cardiovascular diseases. Indeed, a 
working concept for many chronic diseases is that increased oxidant stress is maladaptive and 
promotes disease progression and severity. Increased oxidative stress may also represent a 
shared pathophysiological condition between CVD and NAFLD. In fact, abundant studies 
described increased oxidative stress in a number of chronic diseases, such as metabolic 
syndrome, hypercholesterolemia, obesity, peripheral artery disease and obstructive sleep 
apnea syndrome all associated to NAFLD and increased CVD risk (Bhatia LS 2012) (Targher 
G 2008). General agreement emerging from these studies indicates that patients with NASH 
are at higher risk of cardiovascular diseases than those with simple steatosis, emphasizing the 
role of chronic inflammation caused by oxidative stress in these patients. In fact, in different 
clinical studies in adults and children with NAFLD have been found elevated systemic 
markers of oxidative stress and lipid peroxidation (Yesilova Z 2005) (Nobili V 2010).  
To investigate the shared antioxidant role of LCARN supplementation in heart, we 
quantified the ROS level after immunofluorescent assay. As showed in Figure 19, the ROS 
level significantly decrease in MCDD+LCARN group compared with the MCDD group.  
Due to the particularly elegant relationship between the structure and function of the 
kinase, CaMKII is able to translate a diverse set of signaling events into downstream 
physiological effects. Excessive CaMKII activity promotes cardiomyocyte death, likely by 
mitochondrial and extramitochondrial pathways. Similarly, elevated ROS contributes to 
cardiomyocyte death. Based on these hypothesis, Anderson and collaborators demonstrated 
that CaMKII is a necessary connection between ROS and cardiomyocyte death (Anderson 
ME 2015). They reported that CaMKII is activated by ROS and proposed a potentially wider 
role for CaMKII in physiological and pathological responses to cardiac oxidant stress. These 
observations suggested that oxidation-dependent CaMKII activity plays a critical role in 
numerous pathological processes in the heart. 
As shown in Figure 20, western blot analysis of pCaMKIIα level reveled that this 
kinase was significantly increased only in MCDD mice group. These results support the 
hypothesis that cardiac CaMKII might be activated by ROS and LCARN supplementation 
could ameliorate cardiac stress condition. CaMKII activity is increased in myocardium under 
stress conditions, such as hypertrophy, where oxidation is also elevated. 
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Figure 19. The effect of LCARN supplementation on cardiac ROS level. Staining of ROS mice hearts 
and relative quantification. ROS Anova p=0,0028; Tukey's multiple comparisons test **p=0,0026 CONTR vs. 
MCDD, *p=0,013 MCDD vs. MCDD+LCARN. 
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Figure 20. The effect of LCARN supplementation in cardiac stress at the end of the experiment. 
Western blot analysis of pCaMKIIα protein level in the three mice groups. Data are expressed as fold changes 
(FC) ±SD. pCaMKIIα Anova test p≤0.0199; Tukey's multiple comparisons test *p=0.02 CONTR vs. MCDD. 
 
An increased CaMKII activity consequent activates the AMP-activated protein kinase 
(AMPK). One of the many important cellular control systems is AMPK, which is the putative 
metabolic or energy sensor of the cell. AMPK signaling appears to have broad implications in 
cardiovascular health and disease (Shirwany NA 2010). AMPK signaling has a specific 
physiological role in the heart; its importance is accentuated under conditions that place a 
stress on this organ. For example, AMPK activates the glycolytic pathway, enhances fatty 
acid β-oxidation and improves ATP availability. Cardiac hypertrophy can develop under 
physiological conditions as is seen in trained athletes as a compensatory response to intense 
exercise. It can also occur pathologically in response to different conditions. In recent years, 
evidence has begun to emerge that AMPK can modulate the development of cardiac 
hypertrophy and interestingly, reports suggest that pharmacological activation of AMPK can 
mitigate the hypertrophy (Juric D 2007) (Russell RR 3rd 2004). In conclusion, in the heart 
signaling by AMPK appears to regulate the bioenergetic status of the cardiomyocyte as well 
as maintain the heart muscle in optimum condition. 
To investigate the AMPK level and the role of LCARN supplementation in heart, we 
performed an immunofluorescent assay. As showed in Figure 21, LCARN supplementation is 
seemed to restore the AMPKα 1/2 level compared with the control group and there was no 
significantly difference of AMPKα level between CONTR group and MCDD+LCARN group.  
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Figure 21. The effect of LCARN supplementation in cardiac stress. Immunofluorescence assay and 
relative quantification, confirmed a significant decrease of AMPKα 1/2 protein expression in MCDD group 
mice. AMPKα 1/2 Anova p=0,0473; Tukey's multiple comparisons test *p=0,0399 CONTR vs. MCDD. 
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The role of LCARN in the cardiac fibrosis mechanism 
Consistently with liver findings, we observed fibrotic area also in heart tissue with 
MG-staining as shown in Figure 18C. To confirm these data, we investigated by western blot 
technique the pERK2/ERK2 protein level in cardiomyocytes. ERK1/2 pathway is a central 
downstream signaling pathway that is activated in cardiac muscle cells during hypertrophy 
(Liang Y 2016). As shown in Figure 22A, LCARN supplementation significantly decreased 
pERK2/ERK2. 
We also investigated the role of the signal transducer and activator of transcription 3 
(STAT3). STAT3 mediated intra- and intercellular communication within the heterogeneous 
cellular network of the myocardium to coordinate complex biological processes. STAT3 
modulates proliferation, differentiation, survival, oxidative stress, and/or metabolism in 
cardiomyocytes, fibroblasts, endothelial cells, progenitor cells, and various inflammatory cells 
(Haghikia A 2016). In Figure 22B, western blot analysis shows the LCARN supplementation 
role on pSTAT3/STAT3 protein level. LCARN supplementation significantly decreased 
pSTAT3/STAT3 protein level that on the contrary is significantly increased in the MCDD 
mice group. 
Finally, cardiac fibrosis is characterized by the excessive deposition of collagens and 
extracellular matrix proteins (ECM) that lead to impaired organ function. Fibroblasts are the 
predominant cell type responsible for the homeostatic maintenance of tissue ECM, healing 
after injury. Myofibroblasts are characterized by increased protein synthesis, including 
collagens, other ECM proteins, certain cytokines and α-smooth muscle actin (αSMA), a 
contractile protein and marker of profibrogenic cardiac fibroblasts activation (van Putten S 
2016). As studied in the liver with immunofluorescence assay, we analyzed cardiac αSMA 
level. LCARN supplementation, as showed in Figure 23, significantly decreased αSMA level 
compared to MCDD group and confirming once again the delay of the fibrosis progression.  
52 
 
 
 
 
Figure 22. LCARN supplementation role in the cardiac fibrosis mechanism at the end of the 
experiment. A) Western blot analysis of LCARN supplementation effect on pERK2/ERK2 protein level in the 
three mice group. B) Western blot analysis of LCARN supplementation effect on pSTAT3/STAT protein level in 
the three mice group. Data are expressed as fold changes (FC) ±SD. pERK2/ERK2 Anova test p≤0.0062; 
Tukey's multiple comparisons test **p=0.001 CONTR vs. MCDD, *p=0.02 MCDD vs. MCDD+LCARN. 
pSTAT3/STAT3 Anova test p≤0.0001; Tukey's multiple comparisons test ***p=0.0003 CONTR vs. MCDD, 
*p=0.01 CONTR vs. MCDD+LCARN, ****p<0.0001 MCDD vs. MCDD+LCARN. 
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Figure 23. LCARN supplementation role in the development and control of heart fibrosis. 
Immunofluorescence assay described LCARN supplementation action on αSMA level (20X). αSMA Anova 
p=0,0437; Tukey's multiple comparisons test *p=0,0385 MCDD vs. MCDD+LCARN. 
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7. DISCUSSION 
In this study, we investigated the effect of LCARN supplementation both in the liver 
and in the myocardium of C57BL/6 male mice fed a MCD diet for nr. 6 weeks. The MCD diet 
leads to the development of steatohepatitis with fibrosis and serves as animal model for 
NAFLD. The MCD diet is essential for hepatic β-oxidation and production of VLDL and 
methionine/choline deficiency impairs hepatic VLDL secretion. Consequentially, lipids are 
accumulated in the liver. In addition, cytokines changes, oxidative stress and adipocytokines 
occur, contributing to the liver injury (Ibrahim SH 2016). Our animal model not presented 
accumulation of lipid droplets in the myocardium as Salamone and collaborators found in 
myocardial tissue (Salamone F 2012), probably caused by the different mice group (six-week-
old male BKS, Cg-m
+
/
+
 Lepr
db
/J - db/db - obese mice and six-week-old male heterozygous 
db/m lean as control mice) and the dissimilar weeks of MCD diet somministration (all mice 
were fed a MCD diet for 4 weeks). Despite these differences, in our study, we demonstrated 
the effects of LCARN supplementation on hepatocyte ballooning, oxidative stress induced by 
the disease progression and fibrosis development in liver. In addition, LCARN 
supplementation controlled the induction of cellular stress responses in the myocardium.  
ROS production is a highly regulated process that deeply affects cellular function and 
homoeostasis in all organisms. In eukaryotic cells, ROS are generated in multiple organelles 
including the ER and mitochondria as by product of oxidative protein folding, mitochondrial 
respiration and detoxification. Several evidences suggest that oxidative stress and lipid 
peroxidation has been implicated in the pathogenesis of NAFLD/NASH (Wei Y 2008) 
(Negre-Salvayre A 2010). The role of oxidative stress in NAFLD pathogenesis has been 
discussed in relation to metabolic changes and pro-inflammatory transcription factor 
expression. Inhibition of mitochondrial fatty acid oxidation is thought to be a major cause for 
intrahepatic lipid accumulation and it has been further suggested that impaired hepatic lipid 
clearance via VLDL may be a possible cause of hepatic lipid accumulation in NAFLD 
(Ashraf NU 2015) (Anderson N 2008) (Zhang D 2007). Carnitine plays a vital role in 
conveying long-chain fatty acids from the cytoplasm to the mitochondria, where they are used 
as a source of energy via β-oxidation. Several recent studies have suggested a potential role of 
LCARN in the treatment of lipotoxicity and steatohepatitis. LCARN enhances both lipolysis 
and fatty acid oxidation in NAFLD (Jun DW 2011). Our recent in vitro work on HepG2 cells 
(Montesano A Under Submission), verified that LCARN supplementation can reduce HepG2 
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intracellular lipid accumulation and this in vitro study confirmed the potential effect of 
LCARN supplementation on hepatic lipid droplets formation and oxidative stress response.  
Recent results, indicate that AMP-activated protein kinase (AMPK) is responsible for 
the incidence of NAFLD and regulates hepatic lipid metabolism including lipid biogenesis 
and uptake, fatty acid oxidation, triglyceride and cholesterol metabolism. Furthermore, 
suppression of AMPK induces the lipid accumulation in the hepatocytes, decreases the ability 
of mitochondria to oxidize free fatty acids, and subsequently increases production of ROS, 
which trigger inflammation and ultimately results in the progression from NAFLD to NASH 
(Qiang X 2016). AMPK is activated by the kinase CaMKII an ubiquitous enzyme with a 
mitochondrial localization. In liver, LCARN supplementation showed a significantly 
improvement of pCaMKII level as observed in our previous in vitro study (Montesano A 
Under Submission). In myocardium, LCARN supplementation limited the increase of 
pCaMKII level that is significantly revealed in MCDD group. The pCaMKII increase in 
MCDD mice myocardium did not affect AMPK level that was significantly lower compared 
to the CONTR diet. On the contrary, LCARN supplementation showed a tendency to improve 
cardiac level of AMPK that represents the key regulator of energy metabolism in the heart. 
In the “Two Hits Hypothesis” (Day CP 1998) an oxidative stress condition caused by 
lipid accumulation in the liver, is capable of inducing enough lipid peroxidation that 
overcome the normal cellular defense mechanisms and produce inflammation and fibrosis 
(Tariq Z 2014). During hepatic fibrogenesis, HSCs represent the key fibrogenic elements in 
response to chronic liver injury (Chen RJ 2015) (Friedman SL 2010) (Gressner AM 1996). 
HSCs undergo trans-differentiation from a quiescent into an activated phenotype state 
characterized by an increase expression of αSMA (Barbero-Becerra VJ 2015). αSMA is an 
actin isoform that is normally confined to vascular smooth muscle cells, but is also expressed 
in healing wounds and both hepatic and heart fibro-contractive lesions (Wang J 2005). In this 
work, LCARN supplementation showed a role in limit αSMA level both in liver and heart 
tissues. Interesting, we reported that this supplementation dose acted also on hepatic ERK 
levels and counteracted this protein increase during the disease progression. It has been 
reported the involvement of ERK1/2 in cellular response to oxidative stress and activation of 
ERK1/2 is also required to prevent the development of NASH. (Martindale JL 2002) 
(Aghazadeh S 2002). Furthermore, ERK activity and phosphorylation are then critical in 
altering the cardiac myocyte response to stress-induced hypertrophy and disease progression 
(Jun DW 2011) (Bueno OF 2000). Our results demonstrated the effect of LCARN 
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supplementation in decreasing ERK level in cardiomyocytes, confirming once again its effect 
on the disease progression. 
Stimuli initiating HSCs activation derive from injured hepatocytes, neighboring 
endothelial and Kupffer cells. Hepatocytes and Kupffer cells are a potent source of reactive 
oxygen intermediates and these compounds exert paracrine stimulation of stellate cells in 
myofibroblasts. Moreover, their activity is amplified in vivo by depletion of antioxidants as 
typically occurs in diseased liver (Friedman SL 2000). It is known that fibrosis is a reversible 
process, and fibrotic tissue can be spontaneously resorbed once the injurious stimulus is over 
(Friedman SL 2012). Central to fibrosis regression is the programmed death of activated 
HSCs in response to apoptotic stimuli, which limits the number of cells performing scar tissue 
deposition (Iredale JP 1998). PPARs are a family of nuclear ligand-activated transcription 
factors regulating metabolism, above all the lipid one, in inflammation, cell growth and 
differentiation. PPARγ is mainly known for its central role in driving adipogenesis and lipid 
metabolism, since it promotes the expression of genes involved in lipid uptake and storage 
and it is poorly expressed in the liver (Panebianco C 2016). Moreover, PPARγ has a 
protective role against liver fibrosis, since in vivo fibrogenesis upon injury turned out to be 
decreased in PPARγ-depleted and enhanced in PPARγ-overexpressing rat livers (Wang Z 
2011) (Yang L 2006). This modulation of liver fibrosis by PPARγ is likely due to its effect on 
HSCs, since PPARγ agonists, ectopic expression of PPARγ or treatment with the adipocyte 
differentiation mix in activated HSCs, were shown to inhibit proliferation, induce apoptosis 
and cell cycle arrest and promote reversal from an activated to a quiescent state (Hazra S 
2004) (Yu J 2010). PPARγ also inhibits the expression of the inducible nitric oxide synthase 
and inhibits gene expression in part by antagonizing the activities of the transcription factors 
as NFκB (Ricote M 1998). Our results shown that LCARN supplementation in liver controls 
the fibrosis progression and also significantly increased PPARγ level and consequently 
reduced NFκB p65.  
Finally, in order to investigate the parallel action of LCARN supplementation on 
cardiac fibroblasts proliferation, we analyzed STAT3 activity. STAT3 has been shown to be 
an integral part of the responses of the myocardium to various cardiac insults, including 
myocardial infarction, oxidative damage, myocarditis, hypertrophy and remodeling (Dai B 
2013). STAT protein sequences contains highly conserved ERK phosphorylation sites; and 
therefore STAT protein can be activated by ERK (Ng DC 2001). The cross-talk between these 
two signaling cascades has been shown to participate in a series of physiological and 
pathological processes (Fischer P 2007). Based on our pERK2/ERK2 results, LCARN 
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supplementation showed the ability to significantly reduce the pSTAT3/STAT3 level in 
cardiomyocytes.  
Taken together, these results demonstrated that the supplementation effects of LCARN 
could act on both liver and cardiac hits. As show in Figure 24, the fundamental mechanism 
during the progression of NAFLD and the consequent CVD risk is the oxidative stress. In 
liver, LCARN acted on lipid accumulation and consequently controlled the oxidative stress 
imbalance. We also demonstrated that LCARN acts in this shared mechanism in both tissue 
and its central role is to control the oxidative stress resulting to delaying the fibrosis 
progression.  
 
Figure 24. Possible pathophysiological mechanisms linking NAFLD/NASH to CVD and the possible 
role of LCARN supplementation in the control of disease progression and complications. 
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8. CONCLUSIONS 
In recent years, the effects of nutraceuticals on NAFLD and on cardiovascular disease 
received increasing attention as possible treatment. We have demonstrated that LCARN 
supplementation decreased the severity of experimental NAFLD progression via different 
mechanism likely to involve the lipid accumulation in liver, oxidative stress imbalance and 
fibrosis accumulation in both liver and cardiac tissues analyzed.  
Our data are consistent with the proposition that oxidative stress represents an 
important stimulus in this model of NAFLD progression. Another important point of our 
results is the potential role of LCARN in modulating the shared oxidative stress mechanism 
pathway involved in heart.  
Further studies are required to determine whether a long-term LCARN 
supplementation is able to control the pathophysiologic evolution of the disease and related 
complications. 
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